Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus platinum-etoposide followed by consolidation radiotherapy in oligometastatic extensive-stage small cell lung cancer
ChiCTR2200062648Phase 2Not yet recruiting
- Sponsor
- Cancer Center of Guangzhou Medical University
- Start
- Aug 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in small cell lung cancer (SCLC), sponsored by Cancer Center of Guangzhou Medical University. Primary endpoint: Overall survival. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2200062648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062648.